Filtrera efter Last updated date SelectEfterFöreFrom - To Date Slutdatum Denna vecka Den här månaden Förra veckan Förra månaden Category HumanCorporateVeterinaryHerbal Topic MedicinesCOVID-19PharmacovigilanceVaccinesReferralsPaediatricsRare diseasesRegulatory and procedural guidanceClinical trialsAdvanced therapiesData on medicinesCompliance and inspectionsInnovationMedicine shortagesResearch and developmentBiosimilarsSMEAntimicrobial resistanceCorporateGovernanceBrexitQuality of medicinesGeneric and hybrid medicinesEarly accessMedicines for use outside the EUFeesProduct informationScientific adviceMedical devicesMaximum residue limitMpoxBiologicalsScientific guidelinesVeterinary limited marketsCompassionate useCareersMedication errorPRIMEParallel distributionProcurement Diseases area Viral diseasesCancerImmune-system diseasesDiabetesNeurodegenerative diseasesCardiovascular diseasesHIV and AIDS Responsible body CHMP CVMP PRAC Management Board COMP PDCO CMDh HMPC CAT Patient safety information Patient safety Lämna detta fält tomt Filter Resultat (3827) Sort by Last update date (new to old)Last update date (old to new)A-ZZ-A Lämna detta fält tomt Meeting highlights from the Committee for Medicinal Products for Veterinary Use (CVMP) 16-18 March 2021 19 mars 2021NewsVeterinaryMedicines COVID-19 Vaccine AstraZeneca: benefits still outweigh the risks despite possible link to rare blood clots with low blood platelets 19 mars 2021NewsHumanCOVID-19Vaccines Investigation of COVID-19 Vaccine AstraZeneca and thromboembolic events continues 16 mars 2021NewsHumanCOVID-19Vaccines EMA’s safety committee continues investigation of COVID-19 Vaccine AstraZeneca and thromboembolic events – further update 15 mars 2021NewsHumanCOVID-19Vaccines EMA Management Board – highlights of March 2021 meeting 12 mars 2021NewsCorporate Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 8-11 March 2021 12 mars 2021NewsHumanCOVID-19PharmacovigilanceReferrals Benefits of ifosfamide solutions continue to outweigh risks EMA’s safety committee (PRAC) has concluded that the benefits of ifosfamide solutions for infusion 12 mars 2021NewsHumanPharmacovigilanceReferrals COVID-19 Vaccine AstraZeneca: PRAC investigating cases of thromboembolic events - vaccine’s benefits currently still outweigh risks - Update 11 mars 2021NewsHumanCOVID-19Vaccines EMA recommends COVID-19 Vaccine Janssen for authorisation in the EU 11 mars 2021NewsHumanCOVID-19Vaccines EMA website briefly unavailable on 15 March 2021 11 mars 2021NewsCorporate 1 … 68 69 70 71 72 Page 72 of 383 73 74 75 76 … 383
Meeting highlights from the Committee for Medicinal Products for Veterinary Use (CVMP) 16-18 March 2021 19 mars 2021NewsVeterinaryMedicines
COVID-19 Vaccine AstraZeneca: benefits still outweigh the risks despite possible link to rare blood clots with low blood platelets 19 mars 2021NewsHumanCOVID-19Vaccines
Investigation of COVID-19 Vaccine AstraZeneca and thromboembolic events continues 16 mars 2021NewsHumanCOVID-19Vaccines
EMA’s safety committee continues investigation of COVID-19 Vaccine AstraZeneca and thromboembolic events – further update 15 mars 2021NewsHumanCOVID-19Vaccines
Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 8-11 March 2021 12 mars 2021NewsHumanCOVID-19PharmacovigilanceReferrals
Benefits of ifosfamide solutions continue to outweigh risks EMA’s safety committee (PRAC) has concluded that the benefits of ifosfamide solutions for infusion 12 mars 2021NewsHumanPharmacovigilanceReferrals
COVID-19 Vaccine AstraZeneca: PRAC investigating cases of thromboembolic events - vaccine’s benefits currently still outweigh risks - Update 11 mars 2021NewsHumanCOVID-19Vaccines
EMA recommends COVID-19 Vaccine Janssen for authorisation in the EU 11 mars 2021NewsHumanCOVID-19Vaccines